Similarly, aldafermin [95], an engineered FGF19 analog, reduced liver fat content and tended to improve fibrosis in a phase 2 trial of patients with NASH, but the primary endpoint was not reached. The gene discussed is FGF19; the disease is metabolic dysfunction-associated steatohepatitis.